International Research in Chinese Medicine
International Research in Chinese Medicine. 2025; 5: (2) ; 10.12208/j.ircm.20250013 .
总浏览量: 130
1 南京中医药大学附属苏州市中医医院 江苏苏州
2 苏州市吴门医派研究院 江苏苏州
*通讯作者： 梁国强,单位： 南京中医药大学附属苏州市中医医院 江苏苏州 苏州市吴门医派研究院 江苏苏州；
糖尿病是一种由胰岛素相对或相对分泌不足以及利用障碍引发的一种慢性疾病，而糖尿病前期是指血糖处在正常与糖尿病之间的一种状态。糖尿病前期虽有可能转化为2型糖尿病，但是也可以延缓转化的进程，甚至逆转为正常的血糖水平。因此本综述旨在综合目前我国对于糖尿病前期的中西医主要防治手段进行整理与汇总。西医以二甲双胍等药物为代表进行干预及危险因素管理为主，中医通过膏方、经典方剂（如消渴方、六味地黄丸）进行整体调理，中西医结合则在控糖与改善症状方面具有协同优势。通过生活方式干预（如饮食调整、运动）是预防糖尿病前期进展的基础，未来需加强社区筛查及中药有效成分机制研究，为老年人群预防前期糖尿病恶化提供精准防治策略。
Diabetes is a chronic disease caused by relative or relative lack of insulin secretion and utilization disorders, and prediabetes refers to a state of blood glucose between normal and diabetes. Although pre-diabetes may be transformed into type 2 diabetes, it can also delay the process of transformation and even reverse to normal blood glucose levels. Therefore, this review aims to summarize and summarize the main prevention and treatment methods of Chinese and Western medicine for prediabetes in China. Western medicine primarily focuses on intervention and risk factor management, represented by drugs such as metformin. Traditional Chinese medicine (TCM) employs overall conditioning through paste formulas and classic prescriptions (such as Xiaoke Formula and Liuwei Dihuang Pills). The combination of Western and traditional Chinese medicine has synergistic advantages in controlling blood sugar and improving symptoms. Lifestyle intervention (such as dietary adjustment and exercise) is the foundation for preventing the progression of prediabetes. In the future, it is necessary to strengthen community screening and research on the mechanisms of effective components of traditional Chinese medicine to provide precise prevention and treatment strategies for the elderly population to prevent the deterioration of prediabetes.
[1] International Diabetes Federa tion. IDF Diabetes Atlas, 10th edition [EB/OL]. Brussels, Belgium: 2021; Available at: https :// www.diabetesatlas.org
[2] Xu, Y., Lu, J., Li, M., Wang, T., Wang, K., Cao, Q., Ding, Y., Xiang, Y., Wang, S., Yang, Q., Zhao, X., Zhang, X., Xu, M., Wang, W., Bi, Y., & Ning, G. (2024). Diabetes in China part 1: epidemiology and risk factors [J]. The Lancet Public Health. 2024,9(12):e1089-e1097.
[3] Li Y, Teng D, Shi X, Qin G, Qin Y, Quan H, Shi B, Sun H, Ba J, Chen B, Du J, He L, Lai X, Li Y, Chi H, Liao E, Liu C, Liu L, Tang X, Tong N, Wang G, Zhang JA, Wang Y, Xue Y, Yan L, Yang J, Yang L, Yao Y, Ye Z, Zhang Q, Zhang L, Zhu J, Zhu M, Ning G, Mu Y, Zhao J, Teng W, Shan Z. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study [J]. BMJ. 2020 ,369:M997.
[4] Khan RMM, Chua ZJY, Tan JC, Yang Y, Liao Z, Zhao Y. From Pre-Diabetes to Diabetes: Diagnosis, Treatments and Translational Research[J]. Medicina (Kaunas). 2019, 55(09): 546.
[5] 中华医学会糖尿病学分会.中国糖尿病防治指南（2024版）[J].中华糖尿病杂志,2025,17(01):16-139.
[6] 仝小林,贾伟平,王秀阁,等.糖尿病前期治未病干预指南[J].吉林中医药,2025,45(03):249-255.
[7] 杨茂林.芪玉降糖膏对2型糖尿病的治疗效果分析[J].海峡药学,2021,33(03):134-135.
[8] 朱泳江,富晓旭,谢春光.“饮一溲二”病名病机浅析[J].北京中医药大学学报,2024,47(03):320-324.
[9] 王宇,王鹤迪,陈强,等.中医经典名方治疗糖尿病的研究进展[J].中国实验方剂学杂志,2025,31(04):266-277.
[10] 汪道贵,刘火锋,周华.消渴方加减治疗2型糖尿病肾病患者（气虚血瘀型）的临床研究[J/OL].中华中医药学刊,1-9[2025-05-15].
http://kns.cnki.net/kcms/detail/21.1546.r.20250220.1715.004.html.
[11] 吴海芳,张辉,李淳.何庆勇主任医师运用白虎加人参汤经验[J].中国医药导报,2024,21(15):135-137.
[12] 侯亚莉,张雨,林梅.白虎加人参汤对2型糖尿病患者氧化应激水平与胰岛素敏感性的影响[J].中药药理与临床,2017,33(05):192-194.
[13] 袁晗,邓小敏.六味地黄丸从肾论治糖尿病研究进展[J].光明中医,2024,39(21):4418-4421.
[14] Wenjie Zheng, Gaofeng Wang, Zhe Zhang, Zhenguo Wang, Ke Ma,Research progress on classical traditional Chinese medicine formula Liuwei Dihuang pills in the treatment of type 2 diabetes[J]. Biomedicine & Pharmacotherapy,2020, 121:109564.
[15] Lu X, Xie Q, Pan X, Zhang R, Zhang X, Peng G, Zhang Y, Shen S, Tong N. Type 2 diabetes mellitus in adults: pathogenesis, prevention and therapy[J]. Signal Transduct Target Ther,2024,9(1):262.
[16] International Diabetes Federation. IDF Global Clinical Practice Recommendations for Managing Type 2 Diabetes – 2025.https://idf.org/t2d-cpr-2025.
[17] Warrilow, A., Somerset, S., Pumpa, K. et al.Metformin use in prediabetes: is earlier intervention better? [J]. Acta Diabetol,2020,57(11):1359-1366.
[18] André J Scheen a. SGLT2 inhibitor or GLP-1 receptor agonist in type 2 diabetes? [J]. Revue medicale Suisse. 2019, 14(615):1460-1465.
[19] Ji L, Dong X, Li Y, Li Y, Lim S, Liu M, Ning Z, Rasmussen S, Skjøth TV, Yuan G, Eliaschewitz FG. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30-week, double-blind, phase 3a, randomized trial. Diabetes Obes Metab. 2021, 23(2): 404-414.
[20] 王晓红,王慧,石广珠,等.滋阴清热方联合胰岛素皮下泵治疗初发2型糖尿病患者的临床研究[J].医学食疗与健康,2019,(17):34-35.
[21] Galaviz KI, Weber MB, Suvada K BS, Gujral UP, Wei J, Merchant R, Dharanendra S, Haw JS, Narayan KMV, Ali MK. Interventions for Reversing Prediabetes: A Systematic Review and Meta-Analysis[J]. Am J Prev Med. 2022,62(4):614-625.
[22] Beulens J, Rutters F, Rydén L, Schnell O, Mellbin L, Hart HE, Vos RC. Risk and management of pre-diabetes[J]. Eur J Prev Cardiol. 2019,26(2):47-54.